Paul Tudor Jones's RYTM Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 19,646 shares of Rhythm Pharmaceuticals, Inc. (RYTM) worth $1.71 M, representing 0.00% of the portfolio. First purchased in 2018-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in RYTM, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 74,178 shares. Largest reduction occurred in Q4 2022, reducing 83,796 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Rhythm Pharmaceuticals (RYTM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Rhythm Pharmaceuticals (RYTM) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +19,646 | New Buy | 19,646 | $86.97 |
| Q3 2025 | -4,272 | Sold Out | 0 | $0.00 |
| Q2 2025 | -25,241 | Reduce 85.53% | 4,272 | $63.19 |
| Q1 2025 | +14,268 | Add 93.59% | 29,513 | $52.97 |
| Q4 2024 | +15,245 | New Buy | 15,245 | $55.98 |
| Q2 2024 | -13,355 | Sold Out | 0 | $0.00 |
| Q1 2024 | +8,455 | Add 172.55% | 13,355 | $43.33 |
| Q4 2023 | -24,444 | Reduce 83.30% | 4,900 | $45.97 |
| Q3 2023 | +17,951 | Add 157.56% | 29,344 | $22.92 |
| Q2 2023 | -14,481 | Reduce 55.97% | 11,393 | $16.49 |
| Q1 2023 | +25,874 | New Buy | 25,874 | $0.02 |
| Q4 2022 | -83,796 | Sold Out | 0 | $0.00 |
| Q3 2022 | -41,620 | Reduce 33.19% | 83,796 | $24.50 |
| Q2 2022 | +74,178 | Add 144.77% | 125,416 | $4.15 |
| Q1 2022 | +21,760 | Add 73.82% | 51,238 | $11.51 |
| Q4 2021 | +29,478 | New Buy | 29,478 | $9.97 |
| Q2 2021 | -66,852 | Sold Out | 0 | $0.00 |
| Q1 2021 | +66,852 | New Buy | 66,852 | $21.27 |
| Q3 2018 | -7,758 | Sold Out | 0 | $0.00 |
| Q2 2018 | +7,758 | New Buy | 7,758 | $31.32 |
Paul Tudor Jones's Rhythm Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Rhythm Pharmaceuticals, Inc. (RYTM) in Q2 2018, acquiring 7,758 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Rhythm Pharmaceuticals, Inc. (RYTM) for 20 quarters since Q2 2018.
Paul Tudor Jones's largest addition to Rhythm Pharmaceuticals, Inc. (RYTM) was in Q2 2022, adding 125,416 shares worth $520,000.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 19,646 shares of Rhythm Pharmaceuticals, Inc. (RYTM), valued at approximately $1.71 M.
As of the Q1 2026 filing, Rhythm Pharmaceuticals, Inc. (RYTM) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Rhythm Pharmaceuticals, Inc. (RYTM) was 125,416 shares, as reported at the end of Q2 2022.